Evidence map›Paper›PMID 35901993›Full record

ArticleAmerican journal of infection control2023

Nosocomial COVID-19 at a comprehensive cancer center during the first year of the pandemic: Lessons learned.

Fareed Khawaja, Krithika Srinivasan, Amy Spallone, Adina Feldman, Sherry Cantu, Ella Ariza-Heredia, Tanya Dvordak, Amin Alousi, Sairah Ahmed, Marina George and 3 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of infection control, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Fareed KhawajaDepartment of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX.
Krithika SrinivasanDepartment of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX.
Amy SpalloneDepartment of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX.
Adina FeldmanDepartment of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX.
Sherry CantuDepartment of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX.
Ella Ariza-HerediaDepartment of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX.
Tanya DvordakDepartment of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX.
Amin AlousiDepartment of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX.
Sairah AhmedDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
Marina GeorgeOffice of Chief Operating Officer, The University of Texas MD Anderson Cancer Center, Houston, TX.
Elizabeth FrenzelDepartment of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX.
Micah BhattiDepartment of Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
Roy F ChemalyDepartment of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX; Office of Chief Operating Officer, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: rfchemaly@mdanderson.org.
The University of Texas MD Anderson Cancer Center · US

Funding

Research Training in Infections and ImmunityT32AI055413 · NIAID · BAYLOR COLLEGE OF MEDICINE · PI GIORDANO, THOMAS P, MYSOREKAR, INDIRA U · 2003 to 2024
$3.2M
NIAID NIH HHS T32 AI055413
6 · The paper itself

Abstract

backgroundThe spread of coronavirus disease 2019 (COVID-19) in health care settings endangers patients with cancer. As knowledge of the transmission of COVID-19 emerged, strategies for preventing nosocomial COVID-19 were updated. We describe our early experience with nosocomial respiratory viral infections (RVIs) at a cancer center in the first year of the pandemic (March 2020-March 2021).

methodsNosocomial RVIs were identified through our infection control prospective surveillance program, which conducted epidemiologic investigations of all microbiologically documented RVIs. Data was presented as frequencies and percentages or medians and ranges.

resultsA total of 35 of 3944 (0.9%) documented RVIs were determined to have been nosocomial acquired. Majority of RVIs were due to SARS CoV-2 (13/35; 37%) or by rhinovirus/enterovirus (12/35; 34%). A cluster investigation of the first 3 patients with nosocomial COVID-19 determined that transmission most likely occurred from employees to patients. Five patients (38%) required mechanical ventilation and 4 (31%) died during the same hospital encounter.

conclusionsOur investigation of the cluster led to enhancement of our infection control measures. The implications of COVID-19 vaccination on infection control policies is still unclear and further studies are needed to delineate its impact on the transmission of COVID-19 in a hospital setting.

Indexed as

COVID-19Cross InfectionNeoplasmsCOVID-19 VaccinesHospitalsHumansPandemicsProspective StudiesCOVID-19 VaccinesHospital-associated transmissionImmunocompromisedMalignancyRespiratory virusesSARS CoV-2

Identifiers

PMID35901993
PMCPMC9310434
OpenAlexW4287511329

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.